IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4558
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$203M
Alexander D. Macrae
Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$SGMO SANGAMO THERAPEUTICS, INC | 30 | 30 | 26 | 14 | - | - | -1198.8% | -84.4% | 100.0% | -1663.9% | -1643.7% | 63.2% | 0.0% | 1320.0x | $203M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
SANGAMO THERAPEUTICS, INC (SGMO) receives a "Avoid" rating with a composite score of 29.5/100. It ranks #4558 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for SGMO.
View All RatingsROE proxy -1198.8% (sector -1.9%)
GM 100% vs sector 44%, OM -1664% vs sector 3%
Capital turnover N/A, R&D intensity 320.8%
Rev growth 63%, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate SANGAMO THERAPEUTICS, INC (SGMO) as Avoid with a composite score of 29.5/100 at a current price of $0.47. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
SANGAMO THERAPEUTICS, INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 29.5/100 places it at rank #4558 in our full universe.
No Moat
Very High
Poor
Fair Value
Gross margins of 100% signal strong pricing power.
Stable competitive position in a defensive sector.
Leverage of 1320% D/E amplifies downside risk.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
SANGAMO THERAPEUTICS, INC represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags SANGAMO THERAPEUTICS, INC with an Avoid rating, assigning a composite score of 29.5/100 and 1 out of 5 stars. Ranked #4558 of 7,333 stocks, SGMO falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
SGMO's quality score of 30/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -1198.8% (sector avg: -1.9%), gross margins of 100.0% (sector avg: 44.1%), net margins of -1643.7% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
SGMO registers a value score of just 26/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 22.62x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
SANGAMO THERAPEUTICS, INC's investment score of 36/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 63.2% vs. a sector average of 6.7% and a return on assets of -84.4% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
SANGAMO THERAPEUTICS, INC is experiencing notably weak momentum with a score of just 14/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 63.2% year-over-year, while a beta of 1.26 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
SANGAMO THERAPEUTICS, INC registers a low stability score of 24/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.26 and a debt-to-equity ratio of 1320.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
The short interest score of 40/100 for SGMO suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include above-average market sensitivity (beta: 1.26), elevated leverage (D/E: 1320.00x), micro-cap liquidity risk. With a $203M market cap (micro-cap), SANGAMO THERAPEUTICS, INC may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
SANGAMO THERAPEUTICS, INC is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4558 of 7,333 overall (38th percentile). Key comparisons include ROE of -1198.8% trailing the -1.9% sector median and operating margins of -1663.9% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While SGMO currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (14) would have the largest impact on the composite score.
ROE 62995% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 127% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 66391% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
U.S. stock futures were flat on Tuesday as investors remained cautious ahead of the FOMC meeting. Analysts say the only certainty is that 'things will remain uncertain for the time being'.
This report provides an in-depth analysis of the Cell and Gene Therapy industry, highlighting key company revenues, regulatory approvals, and market trends. It has been compiled by Towards Healthcare, a sister firm of Precedence Research, offering valuable insights into the latest developments and financials in this rapidly advancing field.Ottawa, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cell and gene therapy (CGT) is rapidly advancing, with major players like Novartis, Gilead, and Bristol Myers Squibb
Sangamo Therapeutics (SGMO) stock plunges as the company prices an underwritten stock offering worth $25M, and its Principal Financial Officer exits. Read more here.
Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and CRISPR therapeutics market, highlighting key company performance, pipeline developments, and government initiatives shaping the genetic therapeutics landscape.Ottawa, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The market for gene therapy and CRISPR-based therapeutics continues to grow rapidly, driven by breakthroughs in AAV-based therapies, ex vivo gene editing, and regenerative medicin
Clinical and financing moves put Sangamo Therapeutics (SGMO) in focus Sangamo Therapeutics (SGMO) moved into the spotlight after releasing detailed Phase 1/2 STAAR study data for its Fabry gene therapy candidate, alongside a US$25 million follow on equity offering and a change in its finance leadership. See our latest analysis for Sangamo Therapeutics. Against this backdrop of clinical data, financing and leadership change, Sangamo Therapeutics’ share price has been under pressure, with a 30...